Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
As per the National Cancer Institute estimations, around 71,100 people will be diagnosed with some type of head and neck cancer in the United States in 2024. Out of this, about 16,110 people will die from these diseases. Men are more susceptible to developing the condition when compared to females. Around 69% of the individuals diagnosed with oral cavity or pharynx cancer can survive 5 years or longer from their diagnosis. As a result, there is a high emphasis on providing effective drug alternatives to improve the quality of life of patients across the globe.
The Head and Neck Cancer Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into head and neck cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for head and neck cancer. The head and neck cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The head and neck cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with head and neck cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to head and neck cancer.
Head and neck cancer comprises various types of cancer in the larynx, throat, lips, mouth, nose, or salivary glands. Since it includes multiple indications, the diagnosis can be difficult. Early symptoms mimic common conditions like a sore throat or cold. As a result, the susceptibility to overlook the disease is higher. Prolonged consumption of tobacco and alcohol is amongst the leading causes of head and neck cancer. Around 70% to 80% of these cancers are associated with tobacco use.
There are various types of head and neck cancers. Oral cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, nasopharyngeal cancer and salivary gland cancer are among some common types.
In January 2024, the United States Food and Drug Administration (FDA) approved toripalimab (Loqtorzi), the first immunotherapy drug for nasopharyngeal carcinoma (NPC) treatment. The approval was based on the results of two clinical trials and was sponsored by Shanghai Junshi Biosciences. The trials were conducted across Asia as the prevalence of NPC is considerably higher in the region as compared to other parts of the world.
In May 2024, Petosemtamab also received the FDA's Breakthrough Therapy designation for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) treatment in patients. This bispecific antibody is currently under phase 1/2 trial, wherein the overall response rate (ORR) is around 37%.
The head and neck cancer clinical assessment covers the pathophysiology and epidemiology, developing treatment, and the progress and future aspects of ongoing clinical trials in detail.
This section of the report covers the analysis of head and neck cancer drug candidates based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Route of Administration
EMR’s head and neck cancer report assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II trials cover a major share of the total clinical trials conducted, with approximately 2700 plus head and neck cancer emerging drugs in the pipeline.
The route of administration categories covered under head and neck cancer pipeline analysis include oral, parenteral, and others. The report provides a comparative analysis of the route of administration for each drug in various phases of clinical trials. According to EMR analysis, the parenteral route holds a significant market share based on the route of administration.
The EMR report for the head and neck cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed head and neck cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in head and neck cancer clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs. It covers product description, trial ID, study type, drug class, mode of administration, and recruitment status of head and neck cancer clinical trial drugs.
Cabozantinib and Nivolumab
The combination of these two immunotherapies is being evaluated in the BiCaZo study. The phase 2 trial study intends to identify the positive as well as negative effects of squamous head and neck cancer. Cabozantinib can stop tumor growth while Nivolumab can stimulate the immune system against cancer.
Tadalafil and Pembrolizumab
Currently in a phase 2 study for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), this combination of drugs is under investigation to be in combination. The evaluation also involves checking its efficacy as a combination against the effect of PS-1 inhibition alone.
Ado-Trastuzumab Emtansine
This drug is being investigated to treat HER2-positive salivary gland cancer. The primary objective is to determine if the drug shows improved progression-free survival (PFS) against docetaxel plus trastuzumab (TH) while the secondary objectives include overall response rate comparison. Sponsored by the National Cancer Institute, this drug is under phase 2 trial tests.
M3814 (Peposertib)
As a part of the phase 1 interventional study, this head and neck cancer drug candidate is under investigation to be added to the radiation therapy regime for advanced treatment. The primary objective of the study includes determining the recommended phase 2 dosage for M3814 (Peposertib) when administered in combination with intensity-modulated radiation therapy (IMRT). In addition, the evaluation for its tolerability and safety is also in order.
The Head and Neck Cancer Drug Report provides a strategic overview of the latest and future landscape of treatments for head and neck cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within head and neck cancer pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
Scope of the Report | Details |
Drug Pipeline by Clinical Trial Phase |
|
Route of Administration |
|
Drug Classes |
|
Treatment Type |
|
Leading Sponsors Covered |
|
Geographies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share